These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

691 related articles for article (PubMed ID: 22978645)

  • 1. Retesting for latent tuberculosis in patients with inflammatory bowel disease treated with TNF-α inhibitors.
    Papay P; Primas C; Eser A; Novacek G; Winkler S; Frantal S; Angelberger S; Mikulits A; Dejaco C; Kazemi-Shirazi L; Vogelsang H; Reinisch W
    Aliment Pharmacol Ther; 2012 Nov; 36(9):858-65. PubMed ID: 22978645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Quantiferon-TB Gold versus tuberculin skin test for tuberculosis screening in inflammatory bowel disease patients.
    Andrisani G; Armuzzi A; Papa A; Marzo M; Felice C; Pugliese D; De Vitis I; Rapaccini GL; Guidi L
    J Gastrointestin Liver Dis; 2013 Mar; 22(1):21-5. PubMed ID: 23539386
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Prospective Study to Monitor for Tuberculosis During Anti-tumour Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease and Immune-mediated Inflammatory Diseases.
    Lee CK; Wong SHV; Lui G; Tang W; Tam LS; Ip M; Hung E; Chen M; Wu JC; Ng SC
    J Crohns Colitis; 2018 Jul; 12(8):954-962. PubMed ID: 29757355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of replacing tuberculin skin test with ex vivo interferon γ release assays on decision to administer prophylactic antituberculosis antibiotics before anti-TNF therapy.
    Mariette X; Baron G; Tubach F; Lioté F; Combe B; Miceli-Richard C; Flipo RM; Goupille P; Allez M; Salmon D; Emilie D; Carcelain G; Ravaud P
    Ann Rheum Dis; 2012 Nov; 71(11):1783-90. PubMed ID: 22258485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Positive conversion of tuberculin skin test and performance of interferon release assay to detect hidden tuberculosis infection during anti-tumor necrosis factor agent trial.
    Park JH; Seo GY; Lee JS; Kim TH; Yoo DH
    J Rheumatol; 2009 Oct; 36(10):2158-63. PubMed ID: 19723901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of indeterminate IFN-γ release assay in screening for latent TB in inflammatory bowel diseases.
    Papay P; Eser A; Winkler S; Frantal S; Primas C; Miehsler W; Angelberger S; Novacek G; Mikulits A; Vogelsang H; Reinisch W
    Eur J Clin Invest; 2011 Oct; 41(10):1071-6. PubMed ID: 21413978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors impacting the results of interferon-γ release assay and tuberculin skin test in routine screening for latent tuberculosis in patients with inflammatory bowel diseases.
    Papay P; Eser A; Winkler S; Frantal S; Primas C; Miehsler W; Novacek G; Vogelsang H; Dejaco C; Reinisch W
    Inflamm Bowel Dis; 2011 Jan; 17(1):84-90. PubMed ID: 20722065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How frequently do tuberculosis screening tests convert in inflammatory bowel disease patients on anti-tumour necrosis factor-alpha? A pilot study.
    Bermejo F; Algaba A; Chaparro M; Taxonera C; Garrido E; García-Arata I; Guerra I; Gisbert JP; Olivares D; de-la-Poza G; López-Sanromán A
    Dig Liver Dis; 2013 Sep; 45(9):733-7. PubMed ID: 23587496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Superiority of Interferon Gamma Assay Over Tuberculin Skin Test for Latent Tuberculosis in Inflammatory Bowel Disease Patients in Brazil.
    Amorim RF; Viegas ERC; Carneiro AJV; Esberard BC; Chinem ES; Correa RS; Rodrigues L; Ribeiro-Alves M; Silva KS; de Souza HS; Carvalho ATP
    Dig Dis Sci; 2019 Jul; 64(7):1916-1922. PubMed ID: 30673986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contribution of a heparin-binding haemagglutinin interferon-gamma release assay to the detection of Mycobacterium tuberculosis infection in HIV-infected patients: comparison with the tuberculin skin test and the QuantiFERON-TB Gold In-tube.
    Wyndham-Thomas C; Dirix V; Schepers K; Martin C; Hildebrand M; Goffard JC; Domont F; Libin M; Loyens M; Locht C; Van Vooren JP; Mascart F
    BMC Infect Dis; 2015 Feb; 15():59. PubMed ID: 25886172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnosis of latent tuberculosis infection before initiation of anti-tumor necrosis factor therapy using both tuberculin skin test and QuantiFERON-TB Gold In Tube assay.
    Kim HC; Jo KW; Jung YJ; Yoo B; Lee CK; Kim YG; Yang SK; Byeon JS; Kim KJ; Ye BD; Shim TS
    Scand J Infect Dis; 2014 Nov; 46(11):763-9. PubMed ID: 25195652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of immunosuppressive therapy on QuantiFERON and tuberculin skin test for screening of latent tuberculosis in patients with inflammatory bowel disease scheduled for anti-TNF therapy.
    Mantzaris GJ; Tsironikos D; Tzanetakou X; Grispou E; Karatzas P; Kalogeropoulos I; Papamichael K
    Scand J Gastroenterol; 2015; 50(12):1451-5. PubMed ID: 26139305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Screening for latent tuberculosis infection in patients with chronic inflammatory arthritis: discrepancies between tuberculin skin test and interferon-γ release assay results.
    Costantino F; de Carvalho Bittencourt M; Rat AC; Loeuille D; Dintinger H; Béné MC; Faure G; Chary-Valckenaere I
    J Rheumatol; 2013 Dec; 40(12):1986-93. PubMed ID: 24085550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence of tuberculosis among anti-tumor necrosis factor users in patients with a previous history of tuberculosis.
    Jo KW; Hong Y; Jung YJ; Yoo B; Lee CK; Kim YG; Yang SK; Byeon JS; Kim KJ; Ye BD; Lee SD; Kim WS; Kim DS; Shim TS
    Respir Med; 2013 Nov; 107(11):1797-802. PubMed ID: 24029000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined use of a TST and the T-SPOT®.TB assay for latent tuberculosis infection diagnosis before anti-TNF-α treatment.
    Jung YJ; Lyu J; Yoo B; Lee CK; Kim YG; Yang SK; Byeon JS; Kim KJ; Ye BD; Lee KH; Lee SD; Kim WS; Kim DS; Shim TS
    Int J Tuberc Lung Dis; 2012 Oct; 16(10):1300-6. PubMed ID: 22863375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disease activity is an important factor for indeterminate interferon-γ release assay results in children with inflammatory bowel disease.
    Hradsky O; Ohem J; Zarubova K; Mitrova K; Durilova M; Kotalova R; Nevoral J; Zemanova I; Dryak P; Bronsky J
    J Pediatr Gastroenterol Nutr; 2014 Mar; 58(3):320-4. PubMed ID: 24126833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of interferon-gamma release assay versus tuberculin skin test for tuberculosis screening in inflammatory bowel disease.
    Schoepfer AM; Flogerzi B; Fallegger S; Schaffer T; Mueller S; Nicod L; Seibold F
    Am J Gastroenterol; 2008 Nov; 103(11):2799-806. PubMed ID: 18684188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stringent screening strategy significantly reduces reactivation rates of tuberculosis in patients with inflammatory bowel disease on anti-TNF therapy in tuberculosis endemic region.
    Kumar P; Vuyyuru SK; Kante B; Sahu P; Goyal S; Madhu D; Jain S; Ranjan MK; Mundhra S; Golla R; Singh M; Virmani S; Gupta A; Yadav N; Kalaivani M; Sharma R; Das P; Makharia G; Kedia S; Ahuja V
    Aliment Pharmacol Ther; 2022 Jun; 55(11):1431-1440. PubMed ID: 35229906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tuberculosis screening in Portuguese healthcare workers using the tuberculin skin test and the interferon-gamma release assay.
    Torres Costa J; Sá R; Cardoso MJ; Silva R; Ferreira J; Ribeiro C; Miranda M; Plácido JL; Nienhaus A
    Eur Respir J; 2009 Dec; 34(6):1423-8. PubMed ID: 19948911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequent conversion of tuberculosis screening tests during anti-tumour necrosis factor therapy in patients with rheumatic diseases.
    Hatzara C; Hadziyannis E; Kandili A; Koutsianas C; Makris A; Georgiopoulos G; Vassilopoulos D
    Ann Rheum Dis; 2015 Oct; 74(10):1848-53. PubMed ID: 24854354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.